ATE501248T1 - Stabile wässrige systeme mit proteinen - Google Patents

Stabile wässrige systeme mit proteinen

Info

Publication number
ATE501248T1
ATE501248T1 AT06764894T AT06764894T ATE501248T1 AT E501248 T1 ATE501248 T1 AT E501248T1 AT 06764894 T AT06764894 T AT 06764894T AT 06764894 T AT06764894 T AT 06764894T AT E501248 T1 ATE501248 T1 AT E501248T1
Authority
AT
Austria
Prior art keywords
protein
ionisable groups
stabilising
proteins
aqueous systems
Prior art date
Application number
AT06764894T
Other languages
English (en)
Inventor
Jan Jezek
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE501248(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513653.6A external-priority patent/GB0513653D0/en
Priority claimed from GBGB0610140.6A external-priority patent/GB0610140D0/en
Application filed by Arecor Ltd filed Critical Arecor Ltd
Application granted granted Critical
Publication of ATE501248T1 publication Critical patent/ATE501248T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06764894T 2005-07-02 2006-07-03 Stabile wässrige systeme mit proteinen ATE501248T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0513653.6A GB0513653D0 (en) 2005-07-02 2005-07-02 Protein stability
GBGB0610140.6A GB0610140D0 (en) 2006-05-22 2006-05-22 Protein stability
PCT/GB2006/002470 WO2007003936A1 (en) 2005-07-02 2006-07-03 Stable aqueous systems comprising proteins

Publications (1)

Publication Number Publication Date
ATE501248T1 true ATE501248T1 (de) 2011-03-15

Family

ID=36940697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06764894T ATE501248T1 (de) 2005-07-02 2006-07-03 Stabile wässrige systeme mit proteinen

Country Status (8)

Country Link
US (1) US20090148406A1 (de)
EP (3) EP2264161A1 (de)
JP (1) JP5033798B2 (de)
AT (1) ATE501248T1 (de)
CA (1) CA2614006C (de)
DE (1) DE602006020568D1 (de)
DK (1) DK1899462T3 (de)
WO (1) WO2007003936A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610140D0 (en) 2006-05-22 2006-06-28 Insense Ltd Protein stability
GB2435510A (en) * 2006-02-23 2007-08-29 Mologic Ltd Enzyme detection product and methods
US20090136538A1 (en) * 2006-05-22 2009-05-28 Jan Jezek Stable vaccine formulation
GB0626021D0 (en) 2006-12-29 2007-02-07 Insense Ltd The stabilisation of proteins
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
NZ598881A (en) * 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
JP5273438B2 (ja) * 2007-11-22 2013-08-28 国立大学法人東京農工大学 ペプチド付加生体分子の溶解度計算方法、及びそれを用いたペプチドタグの設計方法と封入体形成防止方法
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
WO2009086400A2 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
WO2009133408A2 (en) 2008-05-01 2009-11-05 Arecor Limited Protein formulation
EP2113564A1 (de) 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
WO2010094906A1 (en) * 2009-07-16 2010-08-26 Arecor Limited The stabilisation of proteins
EP2341940A1 (de) * 2008-07-16 2011-07-13 Arecor Limited Stabilisierung von proteinen
EP2328607A1 (de) 2008-07-16 2011-06-08 Arecor Limited Stabile formulierung eines therapeutischen proteins
DK2349314T3 (da) * 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
MX2011005672A (es) * 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
NZ595694A (en) * 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP3409289B1 (de) 2010-02-26 2020-09-30 Novo Nordisk A/S Stabile, antikörperhaltige zusammensetzungen
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
CN103458926B (zh) 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
GB201113880D0 (en) * 2011-08-12 2011-09-28 Archimed Llp Novel compositions
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2014125237A1 (en) 2013-02-12 2014-08-21 Microarray Limited Novel biosensor
FR3014446B1 (fr) 2013-12-10 2017-05-26 Biomerieux Sa Stabilisation de la gdh en solution aqueuse
CN104480095A (zh) * 2014-11-27 2015-04-01 广西大学 一种酶活力稳定的液态木瓜蛋白酶制剂
US11173197B2 (en) 2015-07-07 2021-11-16 Bluewillow Biologics, Inc. Methods and compositions for nanoemulsion vaccine formulations
EP3319930A4 (de) * 2015-07-07 2019-04-10 NanoBio Corporation Verfahren und zusammensetzungen zur stabilisierung von proteinen
WO2017044367A1 (en) 2015-09-11 2017-03-16 Dow Global Technologies Llc A composition comprising a protein and a polyalkoxy fatty compound
BR112018004394B1 (pt) 2015-09-11 2022-01-18 Rohm And Haas Company Composto graxo de polialcóxi, e, método para fabricação de um composto graxo de polialcóxi

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051627A (en) 1960-08-18 1962-08-28 Armour Pharma Stabilized chymotrypsin solution
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
EP0503583A1 (de) * 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Erythropoietin enthaltendes Arzneimittel mit verzögerter Wirkstofffreigabe
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
IT1247946B (it) 1991-05-17 1995-01-05 Instrumentation Lab Srl Stabilizzazione in forma liquida dell'enzima urato ossidasi
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
SI0948358T2 (sl) 1996-12-24 2012-03-30 Biogen Idec Inc Stabilne tekoče formulacije interferona
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
JP2002125693A (ja) * 2000-10-19 2002-05-08 Toyobo Co Ltd 無細胞タンパク質合成用細胞抽出液組成物
EP1409013B1 (de) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Aluminiumadjuvans und histidin enthaltende impstoffe
JP2005502945A (ja) * 2001-08-30 2005-01-27 ボード オブ レジェンツ,ザ ユニバーシティー オブ テキサス システム タンパク質安定性のpH依存性のアンサンブルに基づく分析
EP1429739A1 (de) * 2001-09-21 2004-06-23 Egalet A/S Polymer-freigabe-system
RU2357751C2 (ru) * 2001-12-21 2009-06-10 Ново Нордиск Хелт Кэр Аг Жидкая композиция полипептидов фактора vii
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
ES2615484T3 (es) * 2002-05-21 2017-06-07 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen grelina
JP2006523609A (ja) * 2002-12-31 2006-10-19 アルタス ファーマシューティカルズ インコーポレイテッド タンパク質結晶およびイオン性ポリマーの複合体
EP1643970A2 (de) * 2003-06-09 2006-04-12 Nastech Pharmaceutical Company Inc. Zusammensetzungen und verfahren für die verbesserte schleimhautabgabe von wachstumshormon
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation

Also Published As

Publication number Publication date
US20090148406A1 (en) 2009-06-11
CA2614006C (en) 2014-11-04
WO2007003936A1 (en) 2007-01-11
DE602006020568D1 (de) 2011-04-21
EP1899462A1 (de) 2008-03-19
CA2614006A1 (en) 2007-01-11
EP2264162A1 (de) 2010-12-22
JP2008544977A (ja) 2008-12-11
JP5033798B2 (ja) 2012-09-26
DK1899462T3 (da) 2011-06-06
EP1899462B1 (de) 2011-03-09
EP2264161A1 (de) 2010-12-22

Similar Documents

Publication Publication Date Title
DE602006020568D1 (de) Stabile wässrige systeme mit proteinen
ATE275378T1 (de) Wässrige kosmetische gele
BRPI0410616A (pt) xampu condicionador
BR0211404A (pt) Aminas, ácidos, aminoácidos e tioéter ácidos substituìdos com perfluoroalquil
BRPI0317696B8 (pt) composição para branqueamento
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
DE59805901D1 (de) Flüssige enzymzubereitung und ihre verwendung
CO6612227A2 (es) Formulaciones concentradas acuosas que contienen saflufenacilo y glifosato
ATE536369T1 (de) Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
DK1309634T3 (da) Vandoplöselige eller vandkvældbare, sulfogruppeholdige, associativt fortykkende copolymerer, fremgangsmåde til fremstilling af samme samt anvendelse deraf
DK1448607T3 (da) Sammensætning og fremgangsmåde til homogen modificering eller krydsbinding af chitosan under neutrale betingelser
ATE512121T1 (de) Verwendung von cersalzen zur inhibierung der abscheidung von mangan in wassersystemen
ATE551381T1 (de) Verfahren zur herstellung von hochkonzentrierte pelletierte additivkonzentrate für polymer
DK0948358T4 (da) Stabile inteferon-væskeformuleringer
BR0014199A (pt) Derivados de bifenila como inibidores de nhe-3
ATE461276T1 (de) Enzymstabilisierung
DE60229958D1 (de) Polymerstabilisierte proteinasen
WO2007057678A3 (en) Pathogen - controlling products
DK1517966T3 (da) Sammensætning på basis af vandig maling, især en lasur eller lak og en kolloid, vandig dispersion af cerium
TR200400639T4 (tr) Donmaya-karşı proteinler, bunların üretimleri ve kullanımları
BR0009265A (pt) Derivados com base em esfingóide e usos destes
BRPI0409564A (pt) sistema estabilizador para polìmeros halogenados
ATE263194T1 (de) Wässrige kunststoff-dispersionen mit erhöhter stabilität
BR0313334A (pt) Uso de polìmeros contendo unidades vinilamina
TR200100387T2 (tr) Alkoksilli amin nötralize aromatik sülfonik asit sürfaktanlar içeren pestisid formülasyonları

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1899462

Country of ref document: EP